计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| C129279-100mg |
100mg |
现货 ![]() |
| |
| C129279-1g |
1g |
现货 ![]() |
| |
| C129279-5g |
5g |
现货 ![]() |
| |
| C129279-10g |
10g |
现货 ![]() |
| |
| C129279-25g |
25g |
现货 ![]() |
| |
| C129279-100g |
100g |
现货 ![]() |
| |
| C129279-500g |
500g |
期货 ![]() |
|
| 别名 | 塞内昔布 | 4-[5-(4-甲苯基)-3-(三氟甲基)-1H-吡唑-1-基]甲磺酰胺 | 5-(4-甲苯基)-1-(4-磺酰基苯基)-3-(三氟甲基)吡唑 |
|---|---|
| 英文别名 | JCX84Q7J1L | 4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide | CELECOXIB (EP MONOGRAPH) | CELECOXIB [EP MONOGRAPH] | CELECOXIB [MART.] | CELECOXIB [USP MONOGRAPH] | DivK1c_000893 | DTXSID0022777 | KBio1_000893 | Celecoxib 100 mg | |
| 规格或纯度 | Moligand™, ≥99% |
| 英文名称 | Celecoxib |
| 生化机理 | 塞来昔布是一种选择性环氧化酶 2(Cox-2)抑制剂(IC50 = 40 nM),对 Cox-1 的敏感性较低。塞来昔布是一种选择性环氧化酶-2(Cox-2)抑制剂(IC50 = 40 nM),对 Cox-1 的敏感性较低。塞来昔布对鼻咽癌(NPC)细胞系具有抗增殖作用,包括 HNE1(IC50 = 32.86 μM)和 CNE1-LMP1(IC50 = 61.31 μM)。非甾体抗炎药。增强体内肿瘤细胞的凋亡。口服有效。 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | 环氧化酶-2 抑制剂 |
| 备注 | 如果有可能,您尽量在使用的当天配置溶液,并在当天使用完它。但是,如果您需要预先配制储备溶液,我们建议您将溶液等份保存在-20°C的密封小瓶中。通常,它们最多可以使用一个月。在使用前和打开样品瓶之前,我们建议您让您的产品在室温下平衡至少1小时。需要更多关于溶解度,用法和处理的建议吗?请访问我们的常见问题(FAQ)页面以获取更多详细信息。 |
| 产品介绍 |
Celecoxib是环氧合酶-2(COX-2)选择性抑制剂,IC50为40 nM。A selective Cox-2 inhibitor Celecoxib is a selective COX-2 inhibitor with IC50 of 40 nM. |
| ALogP | 3.4 |
|---|
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| PubChem SID | 504750587 |
|---|---|
| EC号 | 685-962-5 |
| 分子类型 | 小分子 |
| IUPAC Name | 4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide |
| INCHI | InChI=1S/C17H14F3N3O2S/c1-11-2-4-12(5-3-11)15-10-16(17(18,19)20)22-23(15)13-6-8-14(9-7-13)26(21,24)25/h2-10H,1H3,(H2,21,24,25) |
| InChi Key | RZEKVGVHFLEQIL-UHFFFAOYSA-N |
| Canonical SMILES | CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F |
| Isomeric SMILES | CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F |
| WGK Germany | 3 |
| RTECS | DB2944937 |
| 关联CAS | 169590-42-5 |
| PubChem CID | 2662 |
| NSC Number | 719627 |
| MeSH Entry Terms | 4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide;Celebrex;celecoxib;SC 58635;SC-58635;SC58635 |
| 分子量 | 381.37 |
| 溶解性 | Soluble in DMSO (76 mg/ml at 25 °C), methanol, ethanol (33 mg/ml at 25 °C), water (<1 mg/ml at 25 °C), and dichloromethane., Soluble in DMSO (76 mg/ml at 25 °C), methanol, ethanol (33 mg/ml at 25 °C), water (<1 mg/ml at 25 °C), and dichloromethane |
|---|---|
| 敏感性 | 对热、光线敏感 |
| 熔点 | 163 °C |
| 分子量 | 381.400 g/mol |
| XLogP3 | 3.400 |
| 氢键供体数Hydrogen Bond Donor Count | 1 |
| 氢键受体数Hydrogen Bond Acceptor Count | 7 |
| 可旋转键计数Rotatable Bond Count | 3 |
| 精确质量Exact Mass | 381.076 Da |
| 单同位素质量Monoisotopic Mass | 381.076 Da |
| 拓扑极表面积Topological Polar Surface Area | 86.400 Ų |
| 重原子数Heavy Atom Count | 26 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 577.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| Carbon by Elemental Analysis | 52.5-54(%) |
|---|---|
| Purity(HPLC) | 98-100(%) |
| Nitrogen by Elemental Analysis | 10.4-11.5(%) |
| Appearance(C129279) | White to off-white solid |
| NMR spectrum | Conforms to Structure |
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
| 批号(Lot Number) | 证书类型 | 日期 | 货号 |
|---|---|---|---|
| 分析证书 | 24-06-13 | C129279 | |
| 分析证书 | 24-06-13 | C129279 | |
| 分析证书 | 24-06-13 | C129279 | |
| 分析证书 | 24-03-26 | C129279 | |
| 分析证书 | 24-03-26 | C129279 | |
| 分析证书 | 23-12-04 | C129279 | |
| 分析证书 | 23-12-04 | C129279 | |
| 分析证书 | 23-12-04 | C129279 | |
| 分析证书 | 23-09-22 | C129279 | |
| 分析证书 | 22-08-04 | C129279 | |
| 分析证书 | 22-08-04 | C129279 | |
| 分析证书 | 22-07-04 | C129279 | |
| 分析证书 | 22-07-04 | C129279 | |
| 分析证书 | 22-07-04 | C129279 | |
| 分析证书 | 22-07-04 | C129279 | |
| 分析证书 | 22-07-04 | C129279 | |
| 分析证书 | 22-07-04 | C129279 | |
| 分析证书 | 22-07-04 | C129279 | |
| 分析证书 | 22-07-04 | C129279 |
| 1. Yongjing Cao, Juan Li, Qiangwei Liang, Jiayu Yang, Xiaojie Zhang, Juntao Zhang, Min An, Jiawei Bi, Yanhua Liu. (2023) Tumor Microenvironment Sequential Drug/Gene Delivery Nanosystem for Realizing Multistage Boosting of Cancer–Immunity Cycle on Cancer Immunotherapy. ACS Applied Materials & Interfaces, [PMID:37963093] [10.1021/acsami.3c11394] |
| 2. Xiaoyu Han, Fan Wang, Jieliang Shen, Shuyu Chen, Pengcheng Xiao, Ying Zhu, Weiwei Yi, Zhengyu Zhao, Zhengwei Cai, Wenguo Cui, Dingqun Bai. (2023) Ultrasound Nanobubble Coupling Agent for Effective Noninvasive Deep-Layer Drug Delivery. ADVANCED MATERIALS, (2306993). [PMID:37851922] [10.1002/adma.202306993] |
| 3. Shouchao Xu, Jiehong Yang, Haitong Wan, Li Yu, Yu He. (2023) Combination of Radix Astragali and Safflower Promotes Angiogenesis in Rats with Ischemic Stroke via Silencing PTGS2. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 24 (3): (2126). [PMID:36768450] [10.3390/ijms24032126] |
| 4. Chen An, Cai Peishan, Luo Minqian, Guo Minshan, Cai Ting. (2023) Melt Crystallization of Celecoxib-Carbamazepine Cocrystals with the Synchronized Release of Drugs. PHARMACEUTICAL RESEARCH, 40 (2): (567-577). [PMID:36348133] [10.1007/s11095-022-03427-3] |
| 5. Xin Zhao, Lingyu Li, Shuang Li, Jinyu Liu, Hongya Wang, Yulin Lin, Dayong Cai. (2022) Diammonium glycyrrhizinate ameliorates portal hypertension by regulating portal macrophage oxidation and superoxide dismutase 3. EUROPEAN JOURNAL OF PHARMACOLOGY, 929 (175115). [PMID:35738453] [10.1016/j.ejphar.2022.175115] |
| 6. Cong Zhang, Yuzhen Lu, Yingying Song, Liang Chen, Junjie Hu, Yan Meng, Xin Chen, Shan Li, Guohua Zheng, Zhenpeng Qiu. (2022) Celecoxib attenuates hepatosteatosis by impairing de novo lipogenesis via Akt-dependent lipogenic pathway. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 26 (14): (3995-4006). [PMID:35713152] [10.1111/jcmm.17435] |
| 7. Jialiang Lin, Junchao Huang, Jiang Wu, Bo Tang, Congbin Li, Haijun Xiao. (2022) Poly(lactic acid-co-glycolic acid)-based celecoxib extended-release microspheres for the local treatment of traumatic heterotopic ossification. JOURNAL OF BIOMATERIALS APPLICATIONS, [PMID:35043696] [10.1177/08853282211056937] |
| 8. Changyou Yu, Menghui Yao, Yiming Ma, Yanbo Liu, Shilin Guo, Shijie Xu, Sohrab Rohani, Mingyang Chen, Junbo Gong. (2021) Design of the spherical agglomerate size in crystallization by developing a two-step bridging mechanism and the model. AICHE JOURNAL, 68 (2): (e17526). [10.1002/aic.17526] |
| 9. Muhammad Asim Farooq, Amna Jabeen, Bo Wang. (2021) Formulation, optimization, and characterization of whey protein isolate nanocrystals for celecoxib delivery. JOURNAL OF MICROENCAPSULATION, [PMID:33896352] [10.1080/02652048.2021.1915398] |
| 1. Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, Docter S, Graneto MJ, Lee LF, Malecha JW, Miyashiro JM et al.. (1997) Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).. J Med Chem, 40 (9): (1347-65). [PMID:9135032] |
| 2. Naji S et al.. (2019) Cadmium Induces Migration of Colon Cancer Cells: Roles of Reactive Oxygen Species, P38 and Cyclooxygenase-2.. Cell Physiol Biochem, 52 (6): (1517-1534). [PMID:31120230] |
| 3. Chen L et al.. (2017) L161982 alleviates collagen-induced arthritis in mice by increasing Treg cells and down-regulating Interleukin-17 and monocyte-chemoattractant protein-1 levels.. BMC Musculoskelet Disord, 18 (462). [PMID:29145862] |
| 4. Harati R et al.. (2020) Loss of miR-101-3p Promotes Transmigration of Metastatic Breast Cancer Cells through the Brain Endothelium by Inducing COX-2/MMP1 Signaling.. Pharmaceuticals (Basel), 13 (7): [PMID:32645833] |
| 5. Dey R & Bishayi B. (2020) TLR-2 neutralization potentiates microglial M1 to M2 switching by the combinatorial treatment of ciprofloxacin and dexamethasone during S. aureus infection.. J Neuroimmunol, 344 (577262). [PMID:32450430] |
| 6. Yongjing Cao, Juan Li, Qiangwei Liang, Jiayu Yang, Xiaojie Zhang, Juntao Zhang, Min An, Jiawei Bi, Yanhua Liu. (2023) Tumor Microenvironment Sequential Drug/Gene Delivery Nanosystem for Realizing Multistage Boosting of Cancer–Immunity Cycle on Cancer Immunotherapy. ACS Applied Materials & Interfaces, [PMID:37963093] [10.1021/acsami.3c11394] |
| 7. Xiaoyu Han, Fan Wang, Jieliang Shen, Shuyu Chen, Pengcheng Xiao, Ying Zhu, Weiwei Yi, Zhengyu Zhao, Zhengwei Cai, Wenguo Cui, Dingqun Bai. (2023) Ultrasound Nanobubble Coupling Agent for Effective Noninvasive Deep-Layer Drug Delivery. ADVANCED MATERIALS, (2306993). [PMID:37851922] [10.1002/adma.202306993] |
| 8. Shouchao Xu, Jiehong Yang, Haitong Wan, Li Yu, Yu He. (2023) Combination of Radix Astragali and Safflower Promotes Angiogenesis in Rats with Ischemic Stroke via Silencing PTGS2. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 24 (3): (2126). [PMID:36768450] [10.3390/ijms24032126] |
| 9. Chen An, Cai Peishan, Luo Minqian, Guo Minshan, Cai Ting. (2023) Melt Crystallization of Celecoxib-Carbamazepine Cocrystals with the Synchronized Release of Drugs. PHARMACEUTICAL RESEARCH, 40 (2): (567-577). [PMID:36348133] [10.1007/s11095-022-03427-3] |
| 10. Xin Zhao, Lingyu Li, Shuang Li, Jinyu Liu, Hongya Wang, Yulin Lin, Dayong Cai. (2022) Diammonium glycyrrhizinate ameliorates portal hypertension by regulating portal macrophage oxidation and superoxide dismutase 3. EUROPEAN JOURNAL OF PHARMACOLOGY, 929 (175115). [PMID:35738453] [10.1016/j.ejphar.2022.175115] |
| 11. Cong Zhang, Yuzhen Lu, Yingying Song, Liang Chen, Junjie Hu, Yan Meng, Xin Chen, Shan Li, Guohua Zheng, Zhenpeng Qiu. (2022) Celecoxib attenuates hepatosteatosis by impairing de novo lipogenesis via Akt-dependent lipogenic pathway. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 26 (14): (3995-4006). [PMID:35713152] [10.1111/jcmm.17435] |
| 12. Jialiang Lin, Junchao Huang, Jiang Wu, Bo Tang, Congbin Li, Haijun Xiao. (2022) Poly(lactic acid-co-glycolic acid)-based celecoxib extended-release microspheres for the local treatment of traumatic heterotopic ossification. JOURNAL OF BIOMATERIALS APPLICATIONS, [PMID:35043696] [10.1177/08853282211056937] |
| 13. Changyou Yu, Menghui Yao, Yiming Ma, Yanbo Liu, Shilin Guo, Shijie Xu, Sohrab Rohani, Mingyang Chen, Junbo Gong. (2021) Design of the spherical agglomerate size in crystallization by developing a two-step bridging mechanism and the model. AICHE JOURNAL, 68 (2): (e17526). [10.1002/aic.17526] |
| 14. Muhammad Asim Farooq, Amna Jabeen, Bo Wang. (2021) Formulation, optimization, and characterization of whey protein isolate nanocrystals for celecoxib delivery. JOURNAL OF MICROENCAPSULATION, [PMID:33896352] [10.1080/02652048.2021.1915398] |